hVIVO secures third human challenge trial contract, boosting 2026-27 revenue outlook.

hVIVO PLC has signed its third human challenge trial contract in recent months with a new European biotech client for an influenza trial starting immediately. This contract, alongside others, reflects a significant market recovery after a slowdown in 2025 and strengthens hVIVO's revenue visibility for 2026 and 2027. The company has diversified into four business pillars while expanding its challenge models, maintaining leadership in human challenge trials. hVIVO expects high single-digit growth in 2026, supported by a strong order book and increased contract conversions.